文献速递复苏、休克与脓毒症儿科与产科急症

新生儿液体难治性脓毒性休克的一线血管升压药治疗:随机对照试验的系统评价与Meta分析

First-line vasopressor therapy in neonates with fluid-refractory septic shock: A systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Am J Emerg Med · 2026-06-18
一句话结论4项随机对照试验的Meta分析显示,新生儿液体难治性脓毒性休克中,肾上腺素或去甲肾上腺素与多巴胺在1小时休克逆转和死亡率上无显著差异。

该系统评价与Meta分析纳入4项随机对照试验,评估新生儿(<28日龄)液体难治性脓毒性休克的一线血管升压药治疗,比较肾上腺素或去甲肾上腺素与多巴胺。主要结局为早期休克逆转和全因死亡率,结果显示肾上腺素或去甲肾上腺素与多巴胺相比,1小时内休克逆转无显著差异(RR=1.07;95%CI=0.84-1.36;P=0.57;I²=39%),死亡率也无显著差异(RR=0.95;95%CI=0.80-1.13;P=0.58;I²=0%)。亚组分析显示去甲肾上腺素(RR=0.97;95%CI=0.66-1.44;P=0.90;I²=73%)和肾上腺素(RR=1.16;95%CI=0.86-1.56;P=0.32;I²=0%)均无显著差异,组间也无差异(P=0.48)。次要结局包括需要额外血管活性药物和平均动脉压也无差异。作者认为,由于试验数量有限且研究间存在相当大的临床异质性,这些结果不应被解释为治疗间具有确定性等效。

要点

  • 纳入4项随机对照试验,比较新生儿(<28日龄)液体难治性脓毒性休克中肾上腺素或去甲肾上腺素与多巴胺作为一线血管升压药。
  • 肾上腺素或去甲肾上腺素与多巴胺相比,1小时内休克逆转无显著差异(RR=1.07;95%CI=0.84-1.36;P=0.57;I²=39%)。
  • 肾上腺素或去甲肾上腺素与多巴胺相比,全因死亡率无显著差异(RR=0.95;95%CI=0.80-1.13;P=0.58;I²=0%)。
  • 亚组分析显示去甲肾上腺素(RR=0.97;95%CI=0.66-1.44;P=0.90;I²=73%)和肾上腺素(RR=1.16;95%CI=0.86-1.56;P=0.32;I²=0%)与多巴胺相比均无显著差异,组间也无差异(P=0.48)。
  • 次要结局包括需要额外血管活性药物和平均动脉压无差异;作者认为这些结果不应被解释为治疗间具有确定性等效,需要更多高质量新生儿特异性研究。

适用人群与场景

  • 新生儿(<28日龄)液体难治性脓毒性休克,需要一线血管升压药支持。

研究设计与关键结果

  • 研究类型:随机对照试验的系统评价与Meta分析,纳入4项随机对照试验。
  • 干预与对照:比较肾上腺素或去甲肾上腺素与多巴胺作为一线血管升压药。
  • 主要终点:1小时内休克逆转无显著差异(RR=1.07;95%CI=0.84-1.36;P=0.57;I²=39%);全因死亡率无显著差异(RR=0.95;95%CI=0.80-1.13;P=0.58;I²=0%)。
  • 亚组分析:去甲肾上腺素与多巴胺相比休克逆转无显著差异(RR=0.97;95%CI=0.66-1.44;P=0.90;I²=73%);肾上腺素与多巴胺相比无显著差异(RR=1.16;95%CI=0.86-1.56;P=0.32;I²=0%);亚组间无差异(P=0.48)。
  • 次要终点:需要额外血管活性药物和平均动脉压无差异。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析。
  • 局限:试验数量有限;研究间存在相当大的临床异质性;作者认为结果不应被解释为治疗间具有确定性等效;需要更多高质量新生儿特异性研究以确定最合适的一线治疗。

对床旁实践的改变

  • 作者认为,由于试验数量有限且研究间存在相当大的临床异质性,这些结果不应被解释为治疗间具有确定性等效。
  • 作者认为,需要更多高质量新生儿特异性研究以确定最合适的一线治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Neonates with fluid-refractory septic shock require prompt vasopressor support, including dopamine, epinephrine, and norepinephrine; however, the optimal first-line treatment remains unclear. This meta-analysis assessed the first-line vasopressors for shock reversal and clinical outcomes.

METHODS: A comprehensive search of the PubMed, Scopus, Ovid, and CINAHL databases was performed from inception to April 2026. We included randomized controlled trials evaluating first-line vasopressor therapy in neonates (<28 days old) with fluid-refractory septic shock, comparing epinephrine and norepinephrine with dopamine. The primary outcomes were early shock reversal and all-cause mortality, with secondary outcomes including the need for additional vasoactive agents and changes in hemodynamic responses. Analyses were performed using Review Manager (RevMan) version 5.4 software.

RESULTS: Four RCTs were included. Compared with dopamine, epinephrine or norepinephrine showed no significant difference in shock reversal within 1h (RR = 1.07; 95% CI = 0.84-1.36; P = 0.57; I2 = 39%) or mortality (RR = 0.95; 95% CI = 0.80-1.13; P = 0.58; I2 = 0%). Subgroup analyses showed no significant differences for norepinephrine (RR = 0.97; 95% CI = 0.66-1.44; P = 0.90; I2 = 73%) or epinephrine (RR = 1.16; 95% CI = 0.86-1.56; P = 0.32; I2 = 0%), with no difference between subgroups (P = 0.48). Secondary outcomes including the requirement of additional vasoactive agent, mean arterial pressure were not different.

CONCLUSION: No substantial changes were observed in the vasoactive therapies used in neonates with fluid-refractory septic shock. Nonetheless, owing to the limited number of trials and considerable clinical heterogeneity within the studies, these results should not be construed as definitive equivalency between treatments. Additional high-quality neonatal-specific research with standardized criteria is essential to determine the most appropriate first-line treatment.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Yahya R, Hassoun J, Hamodat O, et al. First-line vasopressor therapy in neonates with fluid-refractory septic shock: A systematic review and meta-analysis of randomized controlled trials. Am J Emerg Med. 2026. PMID: 42361705. doi:10.1016/j.ajem.2026.06.027

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。